Why is Vijaya Diagnostic Centre Ltd falling/rising?

Recent Price Movement and Market Context

The stock has been on a downward trajectory for the past two days, accumulating a loss of 6.84% during this period. On the day in question, it underperformed its sector, Hospital & Healthcare Services, which itself declined by 2.1%. Vijaya Diagnostic Centre’s share price touched an intraday low of ₹926.10, representing a 5.39% fall from previous levels. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure.

Technical indicators further underscore the bearish sentiment, with the stock trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day. This technical weakness often deters short-term traders and can exacerbate downward momentum.

Investor participation has also waned, as evidenced by a 13.22% decline in delivery volume on 02 Mar compared to the five-day average. This reduced engagement suggests cautiousness among shareholders, potentially reflecting concerns about the stock’s near-term prospects.

Performance Relative to Benchmarks

Over the past week, Vijaya Diagnostic Centre’s shares have declined by 5.54%, underperforming the Sensex’s 3.84% fall. While the stock’s one-month loss of 4.49% is marginally better than the Sensex’s 5.61% decline, the year-to-date performance reveals a sharper drop of 11.96% compared to the benchmark’s 7.16% fall. Over the last year, the stock has generated a negative return of 5.82%, contrasting with the Sensex’s positive 8.39% gain. This persistent underperformance relative to the broader market has likely contributed to investor apprehension.

Despite this, the stock has delivered impressive long-term returns, with a three-year gain of 132.38% significantly outpacing the Sensex’s 32.28%. However, the recent trend suggests that investors are focusing more on short- to medium-term challenges.

Fundamental Strengths and Operational Highlights

Vijaya Diagnostic Centre boasts several positive attributes. The company reported its highest quarterly net sales of ₹205.21 crores and a PBDIT of ₹86.06 crores in the December quarter, alongside a PBT less other income of ₹53.12 crores. These figures indicate robust operational performance and efficient management, further supported by a high return on capital employed (ROCE) of 24.22%. The company’s low average debt-to-equity ratio of 0.06 times reflects a conservative capital structure, reducing financial risk.

Institutional investors hold a significant 43.69% stake, suggesting confidence from knowledgeable market participants who typically conduct thorough fundamental analysis before investing.

Valuation Concerns and Growth Challenges

Despite these positives, the stock’s valuation appears stretched. With a ROCE of 21.7 and an enterprise value to capital employed ratio of 10, Vijaya Diagnostic Centre is trading at a premium compared to its peers’ historical averages. This elevated valuation may be deterring new buyers and prompting profit-taking among existing shareholders.

Moreover, the company’s long-term growth rates have been modest, with net sales increasing at an annualised rate of 13.79% and operating profit growing by 8.72% over the past five years. While profits have risen by 12.9% in the last year, the stock’s negative return during the same period has resulted in a high price-to-earnings-growth (PEG) ratio of 4.8, signalling that the market may be pricing in expectations that are difficult to justify based on current growth trends.

This disconnect between valuation and growth, combined with the stock’s underperformance relative to the broader market and sector, has likely contributed to the recent selling pressure.

Conclusion

In summary, Vijaya Diagnostic Centre Ltd’s recent share price decline on 04-Mar is primarily driven by valuation concerns amid a backdrop of underwhelming short-term returns relative to the market and sector. Although the company demonstrates strong operational metrics, efficient management, and low leverage, its premium valuation and modest long-term growth rates have weighed on investor sentiment. The technical weakness and reduced trading volumes further amplify the downward pressure. Investors will likely be monitoring whether the company can sustain its operational momentum and justify its valuation in the coming quarters.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →